Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $76 to $88.
Morgan Stanley Maintains Overweight on Smartsheet, Lowers Price Target to $54
Morgan Stanley analyst Josh Baer maintains Smartsheet (NYSE:SMAR) with a Overweight and lowers the price target from $62 to $54.